Association of osteoarthritis with serum levels of the environmental contaminants perfluorooctanoate and perfluorooctane sulfonate in a large appalachian population

American Journal of Epidemiology

Volumn 174, Issue 4, 2011, Pages 440-450

  Innes, Kim E ^a,b   Ducatman, Alan M ^a   Luster, Michael I ^a   Shankar, Anoop ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Fluorocarbons; hormone replacement therapy; obesity; octanoic acids; osteoarthritis; rheumatic diseases

Indexed keywords

BIOLOGICAL MARKER; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; WATER;

ABNORMALITY; BODY MASS; CHEMICAL POLLUTANT; DEMOGRAPHIC SURVEY; ENVIRONMENTAL FATE; ETIOLOGY; HEALTH SURVEY; LIFESTYLE; METABOLISM; OSTEOLOGY; PATHOGENICITY; POLLUTION EFFECT; POLLUTION EXPOSURE; PUBLIC HEALTH; SERUM;

ADULT; AGED; ARTICLE; BLOOD; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HEALTH SURVEY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OSTEOARTHRITIS; PHYSICIAN; POPULATION RESEARCH; RISK; SERUM; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ALKANESULFONIC ACIDS; APPALACHIAN REGION; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; FLUOROCARBONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OCTANOIC ACIDS; OHIO; OSTEOARTHRITIS; QUESTIONNAIRES; RISK FACTORS; STATISTICS, NONPARAMETRIC; WATER POLLUTANTS; WEST VIRGINIA;

APPALACHIANS; CALIFORNIA; OHIO VALLEY; UNITED STATES;

EID: 80051521863     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr107     Document Type: Article

References (58)

1. Walker JA. Osteoarthritis: pathogenesis, clinical features and management. Nurs Stand. 2009;24(1):35-40.
2. Moskowitz RW. The burden of osteoarthritis: clinical and quality-of-life issues. Am J Manag Care. 2009;15(suppl 8): S223-S229.
3. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008; 9:116. (doi: 10.1186/1471-2474-9-116).
4. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. National Arthritis Data Workgroup. Arthritis Rheum. 2008;58(1):26-35.
5. Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15(suppl 8):S230-S235.
6. Caporali R, Cimmino MA, Sarzi-Puttini P, et al. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin Arthritis Rheum. 2005;35(1 suppl 1):31-37. (Pubitemid 41097253)
7. Rosemann T, Laux G, Szecsenyi J. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. J Orthop Surg Res. 2007;2:12. (doi: 10.1186/1749-799X-2-12).
8. Hochberg MC. Mortality in osteoarthritis. Clin Exp Rheumatol. 2008;26(5 suppl 51):S120-S124.
9. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12):1145-1155. (Pubitemid 37500619)
10. Valdes AM, Spector TD. The contribution of genes to osteoarthritis. Med Clin North Am. 2009;93(1):45-66.
11. Nowatzky J, Howard R, Pillinger MH, et al. The role of uric acid and other crystals in osteoarthritis. Curr Rheumatol Rep. 2010;12(2):142-148.
12. Henrotin Y, Blanco FJ, Aigner T, et al. The significance of oxidative stress in articular cartilage ageing and degradation. Curr Rheumatol Rev. 2007;3(4):261-274. (Pubitemid 350142059)
13. Benjamin M, McGonagle D. Histopathologic changes at "synovio- entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum. 2007;56(11):3601-3609. (Pubitemid 350100693)
14. Brooks P. Inflammation as an important feature of osteoarthritis. Bull World Health Organ. 2003;81(9):689-690.
15. Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008;20(5):565-572.
16. Nishioka M, Ioi H, Matsumoto R, et al. TMJ osteoarthritis/osteoarthrosis and immune system factors in a Japanese sample. Angle Orthod. 2008;78(5):793-798.
17. Kornaat PR, Sharma R, van der Geest RJ, et al. Positive association between increased popliteal artery vessel wall thickness and generalized osteoarthritis: is OA also part of the metabolic syndrome? Skeletal Radiol. 2009;38(12): 1147-1151.
18. Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med. 2009;121(6):9-20.
19. Velasquez MT, Katz JD. Osteoarthritis: another component of metabolic syndrome? Metab Syndr Relat Disord. 2010;8(4):295-305.
20. Lee DH, Steffes M, Jacobs DR. Positive associations of serum concentration of polychlorinated biphenyls or organochlorine pesticides with self-reported arthritis, especially rheumatoid type, in women. Environ Health Perspect. 2007;115(6): 883-888. (Pubitemid 46902243)
21. DeWitt JC, Shnyra A, Badr MZ, et al. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol. 2009;39(1):76-94.
22. Lau C, Anitole K, Hodes C, et al. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci. 2007;99(2):366-394. (Pubitemid 351753056)
23. Calafat AM, Wong LY, Kuklenyik Z, et al. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect. 2007;115(11):1596-1602.
24. Harada KH, Yang HR, Moon CS, et al. Levels of perfluorooctane sulfonate and perfluorooctanoic acid in female serum samples from Japan in 2008, Korea in 1994-2008 and Vietnam in 2007-2008. Chemosphere. 2010;79(3):314-319.
25. Kannan K, Corsolini S, Falandysz J, et al. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol. 2004;38(17):4489-4495. (Pubitemid 39180470)
26. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115(9): 1298-1305. (Pubitemid 47471253)
27. Brede E, Wilhelm M, Göen T, et al. Two-year follow-up biomonitoring pilot study of residents' and controls' PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany. Int J Hyg Environ Health. 2010;213(3): 217-223.
28. Bartell SM, Calafat AM, Lyu C, et al. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect. 2010;118(2):222-228.
29. Eriksen KT, Raaschou-Nielsen O, Sørensen M, et al. Genotoxic potential of the perfluorinated chemicals PFOA, PFOS, PFBS, PFNA and PFHxA in human HepG2 cells. Mutat Res. 2010;700(1-2):39-43.
30. Melzer D, Rice N, Depledge MH, et al. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ Health Perspect. 2010;118(5):686-692.
31. Lin CY, Lin LY, Chiang CK, et al. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am J Gastroenterol. 2010;105(6): 1354-1363.
32. Steenland K, Tinker S, Shankar A, et al. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. Environ Health Perspect. 2010;118(2): 229-233.
33. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect. 2010;118(2):197-202.
34. Steenland K, Tinker S, Frisbee S, et al. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009;170(10):1268-1278.
35. Lin CY, Chen PC, Lin YC, et al. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care. 2009; 32(4):702-707.
36. Frisbee SJ, Shankar A, Knox SS, et al. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med. 2010;164(9):860-869.
37. Qian Y, Ducatman A, Ward R, et al. Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. J Toxicol Environ Health A. 2010;73(12):819-836.
38. Qazi MR, Bogdanska J, Butenhoff JL, et al. High-dose, shortterm exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. Toxicology. 2009;262(3):207-214.
39. Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Prog Lipid Res. 2011;50(2):133-140.
40. Frisbee SJ, Brooks AP Jr, Maher A, et al. The C8 Health Project: design, methods, and participants. Environ Health Perspect. 2009;117(12):1873-1882.
41. March LM, Schwarz JM, Carfrae BH, et al. Clinical validation of self-reported osteoarthritis. Osteoarthritis Cartilage. 1998; 6(2):87-93. (Pubitemid 28149829)
42. MacNeil J, Steenland NK, Shankar A, et al. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ Res. 2009;109(8): 997-1003.
43. Grotle M, Hagen KB, Natvig B, et al. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord. 2008;9:132. (doi: 10.1186/1471-2474-9-132).
44. Liu B, Balkwill A, Cooper C, et al. Reproductive history, hormonal factors and the incidence of hip and knee replacement for osteoarthritis in middle-aged women. Million Women Study Collaborators. Ann Rheum Dis. 2009;68(7): 1165-1170.
45. von Mühlen D, Morton D, von Mühlen CA, et al. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women. J Womens Health Gend Based Med. 2002;11(6):511-518. (Pubitemid 41296430)
46. Wright NC, Riggs GK, Lisse JR, et al. Self-reported osteoarthritis, ethnicity, body mass index, and other associated risk factors in postmenopausal women-results from the Women's Health Initiative. J Am Geriatr Soc. 2008;56(9): 1736-1743.
47. Holbrook TL, Wingard DL, Barrett-Connor E. Self-reported arthritis among men and women in an adult community. J Community Health. 1990;15(3):195-208. (Pubitemid 20336511)
48. Juhakoski R, Heliövaara M, Impivaara O, et al. Risk factors for the development of hip osteoarthritis: a population-based prospective study. Rheumatology (Oxford). 2009;48(1):83-87.
49. Parazzini F. Menopausal status, hormone replacement therapy use and risk of self-reported physician-diagnosed osteoarthritis in women attending menopause clinics in Italy. Progretto Menopausa Italia Study Group. Maturitas. 2003;46(3): 207-212. (Pubitemid 37338408)
50. Singh G, Miller JD, Lee FH, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care. 2002;8(suppl 15):S383-S391. (Pubitemid 35282599)
51. Calich AL, Domiciano DS, Fuller R. Osteoarthritis: can anticytokine therapy play a role in treatment? Clin Rheumatol. 2010;29(5):451-455.
52. Vanden Heuvel JP, Thompson JT, Frame SR, et al. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptoralpha,-beta, and-gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. 2006;92(2):476-489. (Pubitemid 44018964)
53. Lefebvre P, Chinetti G, Fruchart JC, et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116(3):571-580. (Pubitemid 43326861)
54. Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol. 2007;21(3):231-244. (Pubitemid 46800478)
55. Zandbergen F, Plutzky J. PPARa in atherosclerosis and inflammation. Biochim Biophys Acta. 2007;1771(8):972-982.
56. Diep QN, Amiri F, Touyz RM, et al. PPARa activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40(6):866-871. (Pubitemid 35434908)
57. Giaginis C, Giagini A, Theocharis S. Peroxisome proliferatoractivated receptor-gamma (PPAR-γ) ligands as potential therapeutic agents to treat arthritis. Pharmacol Res. 2009; 60(3):160-169.
58. Goldring SR. Role of bone in osteoarthritis pathogenesis. Med Clin North Am. 2009;93(1):25-35.